Legacy Healthcare's CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older
RegulatoryapprovedCINAINU®Positive
AI Analysis
Summary
Legacy Healthcare announced that the FDA has granted Breakthrough Therapy Designation to CINAINU® (LH-8) for alopecia areata in adults, adolescents and children aged 2 years and older, recognizing the potential of this botanical prescription drug candidate.
Outcome Details
FDA Breakthrough Therapy Designation granted
Importance:8/10
Sentiment:
0.85
FDABreakthrough Therapy DesignationAlopecia AreataDermatologyBotanical Drug
Read the original article
Published by PR Newswire Biotech on October 13, 2026 1:15 PM